(BLINCYTO is registered trademarks Amgen Inc.)
What is BLINCYTO:
BLINCYTO is a medicine that contains Blinatumomab and is available as Vial.
Generic Name: Blinatumomab
Strength: 35 mcg single-dose vial
Company: Amgen Inc.
Packing: Single Vial
Blincyto – Blinatumomab 35 mcg is supplied for Tenders, Emergency imports, Orphan drug, Reference listed drugs, Comparator Drug, Name patient medicine and Innovator samples etc.
In how many countries BLINCYTO is approved for marketing?
BLINCYTO is available/approved in USA and Europe. We can help you to access it in India.
What is BLINCYTO used for?
BLINCYTO (blinatumomab) is used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after receiving chemotherapy.
How can I get BLINCYTO in India?
BLINCYTO is a prescription only drug and is not approved for marketing in India.
The Indian Pharma (IP) is a consulting pharmaceutical company which assists Patients in accessing medicines in India. The Indian Pharma facilitates such access only against valid prescriptions in conformity with all local laws and regulations.
Patients/ Clinicians / Researchers can contact IP at +91-120-4080562 or write to at – email@example.com
We facilitate by-
• Helping in documentation to import the medicine for personal use
• Finding Genuine and reliable source in USA, Europe and Japan
• Ensuring 100% transparency.
BLINCYTO can be shipped to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Jaipur, Lucknow, Cochin and Pune and other cities in India.
The Indian Pharma can facilitate the supply of BLINCYTO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement.
The Indian Pharma does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturers or licensees
Can I get BLINCYTO even if I am not based in India?
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country
The Indian Pharma (IP) can help patients in accessing/importing BLINCYTO, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
We help patients, Doctors, R&D and companies to get access to Blincyto at the lowest price worldwide.
Send your enquiry to find–
BLINCYTO in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
BLINCYTO in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
BLINCYTO in North America – Mexico.
BLINCYTO in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
BLINCYTO in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
BLINCYTO in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
BLINCYTO in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
BLINCYTO in Australia and New Zealand.
How is BLINCYTO used?
BLINCYTO should be administered under the guidance of specialist doctor having experience in managing cancer treatments.
Recommended dose: Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle.
- A single cycle of treatment consists of 4 weeks of continuous intravenous infusion followed by a 2-week treatment-free interval.
- For patients at least 45 kg in weight, in Cycle 1, administer BLINCYTO at 9 mcg/day on Days 1–7 and at 28 mcg/day on Days 8–28. For subsequent cycles, administer BLINCYTO at 28 mcg/day on Days 1–28.
If the patient develops certain serious side effects then doctor may interrupt or stop treatment, or reduce the dose. See the summary of product characteristics on company official website for more information
Are there any side-effects/ adverse reactions/precautions associated with treatment with BLINCYTO?
It is recommended to seek your doctor’s medical advice about side effects
How do I contact The Indian Pharma?
You can use different channel to contact The Indian Pharma (IP)
Tele & Mobile: You can reach us on +91 8826990915 or +91-120-4080562 on any working days.
Email: We can also address your enquiries if sent directly to firstname.lastname@example.org. We will respond within 24 hours after receiving your mail. Please mention detailed enquiry, your contact number with ISD code while sending your mail. We will respond within 1 working days after receiving your query form.
What information do you need to help patient in assisting documentation for BLINCYTO import for personal use?
We will require the following documents to help in documentation for Named-Patient import
- Doctor’s Prescription – We would require prescription from Registered Medical Practitioner Stating Product name, dosage, duration of treatment and diagnosis
- Patient’s Medical history – We would require all test reports and Medical reports of the patient for last 3 months.
- Patient’s Identity card – We will require scan copy of Patient’s identity card and proof of residence to initiate documentation process. You can use copy of Passport, Driving License, Employee ID card or any Photo ID document as your Identity card.